JP2020532508A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532508A5 JP2020532508A5 JP2020511399A JP2020511399A JP2020532508A5 JP 2020532508 A5 JP2020532508 A5 JP 2020532508A5 JP 2020511399 A JP2020511399 A JP 2020511399A JP 2020511399 A JP2020511399 A JP 2020511399A JP 2020532508 A5 JP2020532508 A5 JP 2020532508A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- syndrome
- encephalopathy
- bipyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- -1 (4-benzyl-4-hydroxypiperidine-1-yl) (2,4'-bipyridine-3-yl) Chemical group 0.000 claims 14
- 208000014644 Brain disease Diseases 0.000 claims 10
- 208000032274 Encephalopathy Diseases 0.000 claims 10
- 208000011580 syndromic disease Diseases 0.000 claims 8
- 230000001037 epileptic effect Effects 0.000 claims 7
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims 6
- 229960002036 phenytoin Drugs 0.000 claims 6
- 206010010904 Convulsion Diseases 0.000 claims 5
- XKUZMIUSBMCVPP-UHFFFAOYSA-N soticlestat Chemical compound C1CN(C(=O)C=2C(=NC=CC=2)C=2C=CN=CC=2)CCC1(O)CC1=CC=CC=C1 XKUZMIUSBMCVPP-UHFFFAOYSA-N 0.000 claims 5
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 4
- 239000001961 anticonvulsive agent Substances 0.000 claims 4
- 206010015037 epilepsy Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 102100034746 Cyclin-dependent kinase-like 5 Human genes 0.000 claims 3
- 101710178912 Cyclin-dependent kinase-like 5 Proteins 0.000 claims 3
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 claims 3
- 101000972850 Homo sapiens Glutamate receptor ionotropic, NMDA 2B Proteins 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- LTYDTBHSPIJPEG-UHFFFAOYSA-N 3-methyl-5,5-diphenylimidazolidine-2,4-dione Chemical compound O=C1N(C)C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 LTYDTBHSPIJPEG-UHFFFAOYSA-N 0.000 claims 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 2
- 102100031265 Chromodomain-helicase-DNA-binding protein 2 Human genes 0.000 claims 2
- 101000923091 Danio rerio Aristaless-related homeobox protein Proteins 0.000 claims 2
- 201000007547 Dravet syndrome Diseases 0.000 claims 2
- 101710150822 G protein-regulated inducer of neurite outgrowth 1 Proteins 0.000 claims 2
- 102100022645 Glutamate receptor ionotropic, NMDA 1 Human genes 0.000 claims 2
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 claims 2
- 102100031470 Homeobox protein ARX Human genes 0.000 claims 2
- 101000777079 Homo sapiens Chromodomain-helicase-DNA-binding protein 2 Proteins 0.000 claims 2
- 101000880945 Homo sapiens Down syndrome cell adhesion molecule Proteins 0.000 claims 2
- 101001125242 Homo sapiens Glutamate receptor ionotropic, NMDA 2A Proteins 0.000 claims 2
- 101000923090 Homo sapiens Homeobox protein ARX Proteins 0.000 claims 2
- 101000944018 Homo sapiens Potassium channel subfamily T member 1 Proteins 0.000 claims 2
- 101000994626 Homo sapiens Potassium voltage-gated channel subfamily A member 1 Proteins 0.000 claims 2
- 101000994632 Homo sapiens Potassium voltage-gated channel subfamily A member 2 Proteins 0.000 claims 2
- 101001009074 Homo sapiens Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 Proteins 0.000 claims 2
- 101001072243 Homo sapiens Protocadherin-19 Proteins 0.000 claims 2
- 101000631760 Homo sapiens Sodium channel protein type 1 subunit alpha Proteins 0.000 claims 2
- 101000684826 Homo sapiens Sodium channel protein type 2 subunit alpha Proteins 0.000 claims 2
- 101000654381 Homo sapiens Sodium channel protein type 8 subunit alpha Proteins 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- 108010006746 KCNQ2 Potassium Channel Proteins 0.000 claims 2
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims 2
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 claims 2
- 102100033508 Potassium channel subfamily T member 1 Human genes 0.000 claims 2
- 102100034368 Potassium voltage-gated channel subfamily A member 1 Human genes 0.000 claims 2
- 102100034369 Potassium voltage-gated channel subfamily A member 2 Human genes 0.000 claims 2
- 102100034354 Potassium voltage-gated channel subfamily KQT member 2 Human genes 0.000 claims 2
- 102100027376 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 Human genes 0.000 claims 2
- 102100036389 Protocadherin-19 Human genes 0.000 claims 2
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 claims 2
- 102100028910 Sodium channel protein type 1 subunit alpha Human genes 0.000 claims 2
- 102100023150 Sodium channel protein type 2 subunit alpha Human genes 0.000 claims 2
- 102100031371 Sodium channel protein type 8 subunit alpha Human genes 0.000 claims 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 2
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 claims 2
- 229960000571 acetazolamide Drugs 0.000 claims 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims 2
- 229960003529 diazepam Drugs 0.000 claims 2
- GQPXYJNXTAFDLT-UHFFFAOYSA-L disodium;(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methyl phosphate Chemical compound [Na+].[Na+].O=C1N(COP([O-])(=O)[O-])C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 GQPXYJNXTAFDLT-UHFFFAOYSA-L 0.000 claims 2
- QIALRBLEEWJACW-INIZCTEOSA-N eslicarbazepine acetate Chemical compound CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12 QIALRBLEEWJACW-INIZCTEOSA-N 0.000 claims 2
- 229960003233 eslicarbazepine acetate Drugs 0.000 claims 2
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 claims 2
- 229960002767 ethosuximide Drugs 0.000 claims 2
- PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 claims 2
- 229960002870 gabapentin Drugs 0.000 claims 2
- 239000008187 granular material Substances 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- 229960002623 lacosamide Drugs 0.000 claims 2
- VPPJLAIAVCUEMN-GFCCVEGCSA-N lacosamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1 VPPJLAIAVCUEMN-GFCCVEGCSA-N 0.000 claims 2
- 229960001848 lamotrigine Drugs 0.000 claims 2
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 claims 2
- 229960001454 nitrazepam Drugs 0.000 claims 2
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 claims 2
- 229960001233 pregabalin Drugs 0.000 claims 2
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims 2
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 claims 2
- 229960002393 primidone Drugs 0.000 claims 2
- POGQSBRIGCQNEG-UHFFFAOYSA-N rufinamide Chemical compound N1=NC(C(=O)N)=CN1CC1=C(F)C=CC=C1F POGQSBRIGCQNEG-UHFFFAOYSA-N 0.000 claims 2
- 229960003014 rufinamide Drugs 0.000 claims 2
- 229940084026 sodium valproate Drugs 0.000 claims 2
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims 2
- 229960001897 stiripentol Drugs 0.000 claims 2
- IBLNKMRFIPWSOY-FNORWQNLSA-N stiripentol Chemical compound CC(C)(C)C(O)\C=C\C1=CC=C2OCOC2=C1 IBLNKMRFIPWSOY-FNORWQNLSA-N 0.000 claims 2
- 229960004394 topiramate Drugs 0.000 claims 2
- 229960002911 zonisamide Drugs 0.000 claims 2
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 claims 2
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 claims 1
- 241000004297 Draba Species 0.000 claims 1
- 208000017605 Hodgkin disease nodular sclerosis Diseases 0.000 claims 1
- 206010021750 Infantile Spasms Diseases 0.000 claims 1
- 208000035899 Infantile spasms syndrome Diseases 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 208000035544 Nonketotic hyperglycinaemia Diseases 0.000 claims 1
- 206010061334 Partial seizures Diseases 0.000 claims 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims 1
- 201000006791 West syndrome Diseases 0.000 claims 1
- 229960000623 carbamazepine Drugs 0.000 claims 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 1
- 239000011247 coating layer Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960001582 fenfluramine Drugs 0.000 claims 1
- 201000011205 glycine encephalopathy Diseases 0.000 claims 1
- 230000002267 hypothalamic effect Effects 0.000 claims 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 230000001617 migratory effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960001816 oxcarbazepine Drugs 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 208000009999 tuberous sclerosis Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022199076A JP7469445B2 (ja) | 2017-08-31 | 2022-12-14 | Ｃｎｓ状態の治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762553070P | 2017-08-31 | 2017-08-31 | |
| US62/553,070 | 2017-08-31 | ||
| PCT/JP2018/032949 WO2019045121A1 (en) | 2017-08-31 | 2018-08-30 | TREATMENT OF CNS DISEASES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022199076A Division JP7469445B2 (ja) | 2017-08-31 | 2022-12-14 | Ｃｎｓ状態の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020532508A JP2020532508A (ja) | 2020-11-12 |
| JP2020532508A5 true JP2020532508A5 (enExample) | 2021-09-30 |
| JP7196157B2 JP7196157B2 (ja) | 2022-12-26 |
Family
ID=63722720
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511399A Active JP7196157B2 (ja) | 2017-08-31 | 2018-08-30 | Ｃｎｓ状態の治療 |
| JP2022199076A Active JP7469445B2 (ja) | 2017-08-31 | 2022-12-14 | Ｃｎｓ状態の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022199076A Active JP7469445B2 (ja) | 2017-08-31 | 2022-12-14 | Ｃｎｓ状態の治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11285139B2 (enExample) |
| EP (1) | EP3675852A1 (enExample) |
| JP (2) | JP7196157B2 (enExample) |
| KR (1) | KR102680786B1 (enExample) |
| CN (2) | CN116370475A (enExample) |
| CA (1) | CA3073925A1 (enExample) |
| MX (1) | MX2020001732A (enExample) |
| WO (1) | WO2019045121A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3152410A1 (en) | 2011-10-14 | 2013-04-18 | Sage Therapeutics, Inc. | 3,3-disubstituted 19-nor pregnane compounds, compositions, and uses thereof for the treatment of cns related disorders |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
| CN113527400B (zh) | 2013-04-17 | 2024-06-28 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法 |
| RU2019126333A (ru) | 2013-04-17 | 2019-10-08 | Сейдж Терапьютикс, Инк. | 19-нор нейроактивные стероиды и способы их применения |
| WO2015010054A2 (en) | 2013-07-19 | 2015-01-22 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| AU2014308621C1 (en) | 2013-08-23 | 2022-01-06 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| SMT202000414T1 (it) | 2014-10-16 | 2020-09-10 | Sage Therapeutics Inc | Composizioni e metodi per trattare disturbi del snc |
| MX2021004492A (es) | 2014-10-16 | 2022-12-05 | Sage Therapeutics Inc | Composiciones para el tratamiento de trastornos del snc. |
| ME03749B (me) | 2014-11-27 | 2021-04-20 | Sage Therapeutics Inc | KOMPOZICIJE I POSTUPCIZA LEČENJE POREMEĆAJA CNS-a |
| DK3250210T3 (da) | 2015-01-26 | 2021-03-08 | Sage Therapeutics Inc | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser |
| JP6875996B2 (ja) | 2015-02-20 | 2021-05-26 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド、組成物、およびその使用 |
| CA3030420C (en) | 2016-07-11 | 2025-11-18 | Sage Therapeutics, Inc. | C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE |
| WO2018013613A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| CN115974956A (zh) | 2016-08-23 | 2023-04-18 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体 |
| FI3711758T3 (fi) | 2017-11-14 | 2024-05-13 | Sk Biopharmaceuticals Co Ltd | Karbamaattiyhdisteen käyttö poissaolokohtauksen tai poissaolokohtausepilepsian ehkäisemiseksi, lievittämiseksi tai hoitamiseksi |
| US20210161808A1 (en) * | 2018-07-24 | 2021-06-03 | Zenvision Pharma Llp | Nasal Drug Delivery System of Brivaracetam or Salt Thereof |
| GB2580881A (en) * | 2018-11-30 | 2020-08-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| CN114206900A (zh) | 2019-05-31 | 2022-03-18 | 萨奇治疗股份有限公司 | 神经活性类固醇及其组合物 |
| GB2597312A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597311A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597285A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| WO2022217066A1 (en) * | 2021-04-09 | 2022-10-13 | The Johns Hopkins University | Treatment methods and compositions comprising perampanel |
| CN115487144A (zh) * | 2021-06-18 | 2022-12-20 | 北京万全德众医药生物技术有限公司 | 一种卢非酰胺的口服液制备方法 |
| US20250213547A1 (en) * | 2022-03-18 | 2025-07-03 | Takeda Pharmaceutical Company Limited | Methods of treating neurological diseases |
| WO2024100531A1 (en) * | 2022-11-07 | 2024-05-16 | Takeda Pharmaceutical Company Limited | Method of treating seizure disorders |
| WO2025126159A1 (en) * | 2023-12-15 | 2025-06-19 | Takeda Pharmaceutical Company Limited | A method for treating a neurological disease in a recreational drug user |
| WO2025257799A1 (en) * | 2024-06-14 | 2025-12-18 | Takeda Pharmaceutical Company Limited | Methods of treating dravet syndrome |
| CN121550436B (zh) * | 2026-01-23 | 2026-05-12 | 四川大学华西医院 | 组合物及联合用药方式 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2851087C (en) * | 2011-10-07 | 2019-09-24 | Takeda Pharmaceutical Company Limited | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases |
| WO2014092100A1 (ja) * | 2012-12-11 | 2014-06-19 | 武田薬品工業株式会社 | 複素環化合物 |
| US9598398B2 (en) * | 2013-04-04 | 2017-03-21 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EP3363796B1 (en) | 2015-10-16 | 2021-04-07 | Takeda Pharmaceutical Company Limited | Method for producing heterocyclic compound |
-
2018
- 2018-08-30 CA CA3073925A patent/CA3073925A1/en active Pending
- 2018-08-30 EP EP18782213.5A patent/EP3675852A1/en active Pending
- 2018-08-30 CN CN202310328785.4A patent/CN116370475A/zh active Pending
- 2018-08-30 US US16/642,153 patent/US11285139B2/en active Active
- 2018-08-30 KR KR1020207004753A patent/KR102680786B1/ko active Active
- 2018-08-30 JP JP2020511399A patent/JP7196157B2/ja active Active
- 2018-08-30 MX MX2020001732A patent/MX2020001732A/es unknown
- 2018-08-30 CN CN201880055307.8A patent/CN111065394B/zh active Active
- 2018-08-30 WO PCT/JP2018/032949 patent/WO2019045121A1/en not_active Ceased
-
2022
- 2022-02-16 US US17/673,072 patent/US20220168294A1/en not_active Abandoned
- 2022-08-23 US US17/893,905 patent/US20230087903A1/en not_active Abandoned
- 2022-12-14 JP JP2022199076A patent/JP7469445B2/ja active Active
-
2024
- 2024-09-13 US US18/885,342 patent/US20250281477A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Millea | N-acetylcysteine: multiple clinical applications | |
| ES2716906T3 (es) | Métodos para reducir la tasa de exacerbación de asma mediante el uso de benralizumab | |
| JP2016518387A5 (enExample) | ||
| Hu et al. | Efficacy and safety of stereotactic body radiotherapy combined with camrelizumab and apatinib in patients with hepatocellular carcinoma with portal vein tumor thrombus | |
| JP2013505205A5 (enExample) | ||
| JP2013067645A5 (enExample) | ||
| JP2006504795A5 (enExample) | ||
| JP2009518441A5 (enExample) | ||
| JP2011511072A5 (enExample) | ||
| JP2010540616A5 (enExample) | ||
| JP2018513852A5 (enExample) | ||
| RU2008122358A (ru) | Лекарственные формы, содержащие ag013736 | |
| RU2010147287A (ru) | Комбинированная композиция | |
| JP2012031131A5 (enExample) | ||
| JP2009529502A5 (enExample) | ||
| JP2009543885A5 (enExample) | ||
| JP2019517469A5 (enExample) | ||
| JP2018507243A5 (enExample) | ||
| JP2006513184A5 (enExample) | ||
| KR20140025314A (ko) | 복합 조성물 | |
| CN114224889A (zh) | 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用 | |
| JP2017531043A5 (enExample) | ||
| Rosenberg et al. | Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy | |
| RU2011111792A (ru) | Применение парацетамола и ибупрофена в лечении | |
| JP2012505830A5 (enExample) |